ストックスクリーナーアプリを入手
93.11
1.71%
-1.62
アフターアワーズ：
93.50
0.39
+0.42%
前日終値:
$94.73
開ける：
$94.58
24時間の取引高:
64.40M
Relative Volume:
4.63
時価総額：
$235.20B
収益：
$64.17B
当期純損益:
$17.12B
株価収益率:
13.84
EPS:
6.73
ネットキャッシュフロー:
$18.10B
1週間 パフォーマンス:
-1.54%
1か月 パフォーマンス:
+4.03%
6か月 パフォーマンス:
-20.53%
1年 パフォーマンス:
-24.68%
1日の値動き範囲:
$93.07
$94.68
1週間の範囲:
$93.07
$95.43
52週間の値動き範囲:
$81.04
$134.63
Merck Co Inc Stock (MRK) Company Profile
MRK を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MRK
Merck Co Inc
|
93.11 | 235.20B | 64.17B | 17.12B | 18.10B | 6.73 |
|
LLY
Lilly Eli Co
|
837.57 | 752.28B | 45.04B | 10.59B | 414.30M | 11.71 |
|
ABBV
Abbvie Inc
|
210.01 | 370.74B | 56.33B | 4.28B | 17.83B | 2.40 |
|
JNJ
Johnson Johnson
|
163.63 | 344.63B | 88.82B | 14.07B | 18.06B | 5.79 |
|
NVO
Novo Nordisk Adr
|
76.86 | 341.19B | 42.09B | 14.65B | 10.11B | 3.2833 |
Merck Co Inc Stock (MRK) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-02-18 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2025-02-10 | ダウングレード | TD Cowen | Buy → Hold |
| 2025-01-08 | ダウングレード | Truist | Buy → Hold |
| 2024-12-20 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-10 | 再開されました | BofA Securities | Buy |
| 2024-12-04 | アップグレード | HSBC Securities | Hold → Buy |
| 2024-11-15 | 開始されました | Wolfe Research | Peer Perform |
| 2024-11-11 | ダウングレード | Daiwa Securities | Buy → Neutral |
| 2024-10-17 | 開始されました | Bernstein | Mkt Perform |
| 2024-03-11 | ダウングレード | Societe Generale | Hold → Sell |
| 2024-01-04 | アップグレード | TD Cowen | Market Perform → Outperform |
| 2023-11-09 | 開始されました | Deutsche Bank | Buy |
| 2023-10-27 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2023-10-20 | アップグレード | UBS | Neutral → Buy |
| 2023-07-14 | 開始されました | HSBC Securities | Hold |
| 2023-04-13 | アップグレード | Citigroup | Neutral → Buy |
| 2023-03-28 | ダウングレード | Societe Generale | Buy → Hold |
| 2023-03-13 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2023-03-06 | 開始されました | Jefferies | Buy |
| 2023-02-22 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2023-01-04 | アップグレード | BofA Securities | Neutral → Buy |
| 2022-11-18 | 開始されました | Credit Suisse | Outperform |
| 2022-10-10 | アップグレード | Guggenheim | Neutral → Buy |
| 2022-09-14 | アップグレード | Berenberg | Hold → Buy |
| 2022-07-06 | アップグレード | Daiwa Securities | Neutral → Buy |
| 2022-06-06 | 再開されました | SVB Leerink | Outperform |
| 2022-04-06 | 再開されました | Morgan Stanley | Equal-Weight |
| 2021-12-17 | 開始されました | Goldman | Buy |
| 2021-12-16 | 開始されました | Daiwa Securities | Neutral |
| 2021-12-13 | ダウングレード | UBS | Buy → Neutral |
| 2021-12-09 | 開始されました | Wells Fargo | Overweight |
| 2021-12-07 | ダウングレード | Guggenheim | Buy → Neutral |
| 2021-11-29 | ダウングレード | Citigroup | Buy → Neutral |
| 2021-11-19 | 開始されました | BMO Capital Markets | Market Perform |
| 2021-11-01 | アップグレード | Argus | Hold → Buy |
| 2021-09-07 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-07-27 | 再開されました | Truist | Buy |
| 2021-05-20 | ダウングレード | Argus | Buy → Hold |
| 2021-04-07 | 再開されました | RBC Capital Mkts | Sector Perform |
| 2020-11-10 | 再開されました | Bernstein | Outperform |
| 2020-09-29 | 開始されました | Berenberg | Hold |
| 2020-08-03 | アップグレード | Goldman | Neutral → Buy |
| 2020-06-12 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2020-02-27 | 開始されました | Barclays | Overweight |
| 2020-01-07 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2019-10-17 | 再開されました | BofA/Merrill | Neutral |
| 2019-08-16 | 開始されました | SVB Leerink | Outperform |
| 2019-07-03 | 開始されました | Mizuho | Buy |
| 2019-05-28 | 開始されました | Goldman | Neutral |
| 2019-05-13 | アップグレード | Atlantic Equities | Neutral → Overweight |
| 2018-10-16 | 繰り返されました | Citigroup | Buy |
| 2018-10-09 | 再開されました | Guggenheim | Buy |
| 2018-04-23 | アップグレード | Goldman | Neutral → Buy |
| 2018-04-17 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2018-04-05 | アップグレード | Barclays | Equal Weight → Overweight |
| 2018-03-12 | アップグレード | Leerink Partners | Mkt Perform → Outperform |
| 2018-02-14 | 繰り返されました | Leerink Partners | Mkt Perform |
| 2018-02-07 | 繰り返されました | Morgan Stanley | Equal-Weight |
| 2018-01-16 | アップグレード | SunTrust | Hold → Buy |
すべてを表示
Merck Co Inc (MRK) 最新ニュース
Pharmaceutical Firms Say UK Investment Is 'Unlikely' Unless Payment Levy Is Adressed - Benzinga
Lyophilized Product Market to Witness Remarkable Growth with - openPR
Bragar Eagel & Squire, P.C. Reminds Investors That Class - GlobeNewswire
ROSEN, LEADING INVESTOR COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel - Bluefield Daily Telegraph
ROSEN, LEADING INVESTOR COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – MRK - TradingView
MRK Purchasers Have Opportunity to Lead Merck & Co., Inc. Securities Fraud Lawsuit - PR Newswire
Merck & Co., Inc. (MRK): Among Incredibly Cheap Dividend Stock to Buy Now - Insider Monkey
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Merck & Co. - GlobeNewswire
Why Merck & Co. (MRK) Is Among the Most Undervalued Biotech Stocks to Invest In - Yahoo Finance
Merck & Co., Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your RightsMRK - ACCESS Newswire
MRK SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Merck & Co., Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - Markets Insider
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Merck & Co. - Markets Insider
Merck & Co., Inc. (MRK): A Bull Case Theory - Insider Monkey
Merck & Co's Options: A Look at What the Big Money is Thinking - Benzinga
Class Action Filed Against Merck & Co., Inc. (MRK)April 14, 2025 Deadline to Join – Contact Levi & Korsinsky - GlobeNewswire
MRK INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Merck & Co., Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - Markets Insider
Is Merck & Co Inc. (NYSE:MRK) the Most Undervalued S&P 500 Stock to Buy Now? - Yahoo Finance
Levi & Korsinsky Reminds Merck Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 14, 2025MRK - PR Newswire
Is Merck & Co Inc. (NYSE:MRK) the Most Profitable Value Stock to Buy Now? - Insider Monkey
Shareholders that lost money on Merck & Co., Inc.(MRK) - GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Merck & Co., Inc. of Class Action Lawsuit and Upcoming DeadlinesMRK - PR Newswire
MRK INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Merck & Co., Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - Markets Insider
MRK Investors Have Opportunity to Lead Merck & Co., Inc. Securities Fraud Lawsuit with the Schall Law Firm - Morningstar
Merck & Co., Inc. (MRK): Among Top Dividend Contenders List - Yahoo Finance
2025-03-16 | Shareholders that lost money on Merck & Co., Inc.(MRK) Urged to Join Class ActionContact Levi & Korsinsky to Learn More | NYSE:MRK | Press Release - Stockhouse Publishing
MRK STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Merck & Co., Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - Markets Insider
ROSEN, LEADING INVESTOR COUNSEL, Encourages Merck & Co., - GlobeNewswire
Lost Money on Merck & Co., Inc.(MRK)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - ACCESS Newswire
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Merck & Co. - GlobeNewswire
ROSEN, LEADING INVESTOR COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionMRK - Markets Insider
A Closer Look at Merck & Co's Options Market Dynamics - Benzinga
MRK SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Merck & Co., Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - Markets Insider
Dividend Roundup: Microsoft, Walmart, Target, Merck & Co, and more - Seeking Alpha
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Merck & Co., Inc. (MRK) Shareholders - ACCESS Newswire
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel ... - Bluefield Daily Telegraph
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Merck & Co., - GlobeNewswire
Bioengineered Protein Drugs Market Size to Cross USD 672.7 Billion by 2034, Growing at a CAGR of 6.2% - GlobeNewswire Inc.
Contact Levi & Korsinsky by April 14, 2025 Deadline to Join Class Action Against Merck & Co., Inc. (MRK) - GlobeNewswire
MRK STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Merck & Co., Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - Markets Insider
Merck & Co., Inc. (NYSE:MRK) Looks Interesting, And It's About To Pay A Dividend - Yahoo Finance
Merck & Co., Inc. Class Action: The Gross Law Firm Reminds Merck Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 14, 2025MRK - PR Newswire
Merck & Co.’s SWOT analysis: pharma giant faces challenges amid keytruda dominance - Investing.com India
Merck & Co., Inc. (NYSE:MRK) Receives $116.39 Consensus Target Price from Analysts - Defense World
Kelun Wins World’s First TROP2 ADC Approval In Lung Cancer, Merck Left Out - Citeline News & Insights
How Do Investors Really Feel About Merck & Co? - Benzinga
Why Merck & Co., Inc. (MRK) is the Best Pharma Stock to Buy According to Hedge Funds - Insider Monkey
Merck releases positive phase 3 data on daily oral HIV drug (MRK:NYSE) - Seeking Alpha
Merck's Investigational Two-Drug Regimen Maintained HIV-1 Suppression in Late-Stage Trials - Marketscreener.com
Merck: new treatment option for HIV -March 12, 2025 at 12:16 pm EDT - Marketscreener.com
Merck & Co., Inc. (MRK): Among Dobermans of the Dow to Buy - Insider Monkey
Anti-Inflammatory Therapeutics Market to Reach $125.55 Billion by 2028 | Merck & Co., Inc., GlaxoSmithKline - EIN News
Merck Co Inc (MRK) 財務データ
収益
当期純利益
現金流量
EPS
0.95%
0.32%
大文字化:
|
ボリューム (24 時間):